

18 January 2021 Sydney, Australia

## Appendix 3Y - Change of Director's Interest Notice

**Sydney, 18 January 2021:** Nyrada Inc (ASX: NYR) attaches the Appendix 3Y – Change of Director's Interest Notice for Dr Ian Dixon.

For clarity, this release is exactly the same as the Appendix 3Y released earlier this morning, however is being released under the correct ASX headline (ie Appendix 3Y as opposed to earlier release made under the ASX headline Appendix 3G).

#### **About Nyrada Inc**

Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular, neurological, and inflammatory/autoimmune diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, USA, and the liability of its stockholders is limited.

-ENDS-

Authorised by Mr David Franks, Company Secretary.

www.nyrada.com

**Investor & Corporate Enquiries:** 

Prue Kelly

T: 0459 022 445

E: info@nyrada.com

**Media Enquiries:** 

Catherine Strong Citadel-MAGNUS

T: 02 8234 0111

E: cstrong@citadelmagnus.com

**Company Secretary:** 

**David Franks** 

T: 02 8072 1400

E: David.Franks@automicgroup.com.au

Nyrada Inc. ARBN 625 401 818

Rule 3.19A.2

# **Appendix 3Y**Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/

Name of entity	Nyrada Inc
ARBN	625 401 818

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ian Dixon
Date of last notice	8 September 2020

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect	
Nature of indirect interest (including registered holder)  Note: Provide details of the circumstances giving rise to the relevant interest.	Altnia Holding Pty Ltd <i a="" c="" dixon="" family=""></i>	
Date of change	18 January 2021	
No. of securities held prior to change		
Direct	• Nil	
Altnia Holding Pty Ltd <i a="" c="" dixon="" family=""></i>	<ul> <li>9,921,725 Chess Depositary Interests ("CDI's") (equivalent to 9,921,725 Class A Common Stock) escrowed 24 months from quotation;</li> <li>5,999,400 Performance Shares escrowed 24 months from quotation</li> </ul>	
Class	Unlisted Options under Employee Incentive Plan, Exercise Price is the higher of  i) 100% of the Fair Market Value or  ii) 120% of the VWAP of the Company's  CDIs for the period of 10 trading days ending on the trading day immediately prior to the date on which that option vests	

<sup>+</sup> See chapter 19 for defined terms.

	<ul> <li>comprising:</li> <li>600,000 options will vest upon the first anniversary of the grant date of 18 January 2021, Expiry 3 years from the date on which the option vests);</li> <li>600,000 options will vest upon the second anniversary of the grant date of 18 January 2021 (Expiry 3 years from the date on which the option vests); and</li> <li>600,000 options will vest upon the third anniversary of the grant date of 18 January 2021 (Expiry 3 years from the date on which the option vests).</li> </ul>
Number acquired	Direct: 1,800,000
Number disposed	N/A
Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	N/A – issued as part of Director remuneration package
No. of securities held after change	
Direct	Unlisted Options under Employee Incentive Plan, Exercise Price is the higher of  i) 100% of the Fair Market Value or  ii) 120% of the VWAP of the Company's  CDIs for the period of 10 trading days ending on the trading day immediately prior to the date on which that option vests  comprising:  • 600,000 options will vest upon the first anniversary of the grant date of 18 January 2021, Expiry 3 years from the date on which the option vests);  • 600,000 options will vest upon the second anniversary of the grant date of 18 January 2021 (Expiry 3 years from the date on which the option vests); and  • 600,000 options will vest upon the third anniversary of the grant date of 18 January 2021 (Expiry 3 years from the date on which the option vests).

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3Y Page 2 01/01/2011

Altnia Holding Pty Ltd <i a="" c="" dixon="" family=""></i>	<ol> <li>9,921,725 Chess Depositary Interests ("CDI's") (equivalent to 9,921,725 Class A Common Stock) escrowed 24 months from quotation;</li> <li>5,999,400 Performance Shares escrowed 24 months from quotation</li> </ol>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback	The securities are being issued as part of non-executive Director remuneration, as approved by Shareholders at the 2020 Annual General Meeting on 19 November 2020.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change  Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y Change of Director's Interest Notice

## Part 3 – \*Closed period

Were the interests in the securities or contracts detailed above traded during a *closed period where prior written	No
clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

Appendix 3Y Page 4 01/01/2011

<sup>+</sup> See chapter 19 for defined terms.